LINVATEC BELGIUM
ActiveSummary
The computed 12-month bankruptcy probability of LINVATEC BELGIUM is 2.0% (moderate). The 2024 annual accounts show equity of €182.2m and a net result of €175,414. Equity has been shrinking by about 4% per year since 2018. Its solvency ranks better than 95% of 6,063 sector peers (NACE 46, financial year 2024). The company has been active since 2000 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Official details
Source: KBO- Status
- Active since 18-04-2000 Normal situation
- Activity
- Wholesale of pharmaceutical and medical goods NACE 46460
- Joint committee
- 200 Aanvullend Paritair Comité voor de bedienden · annual accounts 2024
- Establishment unit
- 2.096.515.042 1620 Drogenbos, since 03-05-2000
- Financial year end
- 31 December
- Peppol
- Reachable since 03-12-2025
Board and ownership
- Sven Van KetsManaging director
- Andrew David KearnsManaging director
- Patrick BeyerDirector
- Linvatec Nederland100%annual accounts 2024
- CONMED Corporationconsolidatesannual accounts 2024
- Holdings
- Shares in 1 company CONMED Europe
Financial position
- Bankruptcy probabilitywithin 12 months
- 2.0%
- Profit
- €175,414
- ▲ 15.3%
- Equity
- €182.2m
- ▲ 0.1%
- Total assets
- €182.6m
- =
- Employees on 31-12-2024
- 2
- =
- 2025 accounts not filed, 95 days past the deadline
Score breakdownraises risk1 financial year not filed after the legal deadline; last filed accounts filed 424 days late; 3 of the last 3 accounts lateLiquidity: current ratio 14.16, cash €358,478Figures for financial year 2024 (filed on 30-09-2026)lowers riskFounded in 2000Show the evidence
Checked score
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro). It does better than 90% of them on solvency, 53% on liquidity, 24% on profitability and 41% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 6 accounts on average 369 days after the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (1)
Key points
Recent changes
- · Gazette deed 3 directors appointed, 1 director resigningAppointments: Andrew David Kearns (managing director) and Sven Van Kets (managing director) · Resignation: Stéphane Jean Auguste Epinette (director)
- · Gazette deed 2 directors appointed, 1 director resigningResignation: Patrick Joseph Beyer (director) · Appointments: Stephan Epinette (director) and Sven Van Kets (director)
- · Gazette deed Resignation: Heather Lynn Cohen (director)
Comparable companies
These companies have the same main activity as LINVATEC BELGIUM: wholesale of pharmaceutical and medical goods (NACE 46460). They are comparable in size and age: total assets between €31m and €362m, founded between 1988 and 2015.
| Company | Total assets | Turnover |
|---|---|---|
| LINVATEC BELGIUM Drogenbos | €182.6m | - |
| OMRIX BIOPHARMACEUTICALS Machelen (Brab.) | €66.5m | €107.0m |
| BESINS HEALTHCARE Elsene | €110.7m | €11.1m |
| KANEKA MEDICAL EUROPE Zaventem | €45.1m | €58.0m |
| Mirion Technologies (Canberra BNLS) Asse | €67.4m | €8.8m |
| PORTON EUROPE Turnhout | €31.4m | €64.7m |
| Nipro PharmaPackaging International Mechelen | €362.4m | €2.2m |
Key facts about LINVATEC BELGIUM
- What is the company number of LINVATEC BELGIUM?
- The company number of LINVATEC BELGIUM is 0471.726.242. The VAT number is the same number with BE in front: BE 0471.726.242.
- Where is LINVATEC BELGIUM based?
- The registered office is at W.A. Mozartlaan 3, 1620 Drogenbos.Company details
- What does LINVATEC BELGIUM do?
- According to the KBO register, the main activity is wholesale of pharmaceutical and medical goods (NACE 46460).
- What is the legal form of LINVATEC BELGIUM?
- The legal form of LINVATEC BELGIUM is Public limited company (NV).
- When was LINVATEC BELGIUM founded?
- LINVATEC BELGIUM was founded on 18-04-2000.
- Is LINVATEC BELGIUM still active?
- Yes, LINVATEC BELGIUM is an active enterprise in the KBO register.
- How many employees does LINVATEC BELGIUM have?
- LINVATEC BELGIUM had an average of 1.9 full-time equivalents in financial year 2024, according to the filed annual accounts.Financials
- Which joint committee does LINVATEC BELGIUM fall under?
- In its 2024 annual accounts, LINVATEC BELGIUM states joint committee 200 (Aanvullend Paritair Comité voor de bedienden).
- What is the turnover of LINVATEC BELGIUM?
- The annual accounts for financial year 2024 state no turnover.
- Is LINVATEC BELGIUM profitable?
- In financial year 2024, LINVATEC BELGIUM made a profit of €175,414.
- Where can I find the annual accounts of LINVATEC BELGIUM?
- LINVATEC BELGIUM filed 24 annual accounts with the National Bank of Belgium, the latest for financial year 2024.
Next steps
See how customers, suppliers and banks see your own company and what to improve first.